Clinical Trials at UChicago Medicine Northwest Indiana
As of September 2026, 28 paid clinical trials are recruiting at UChicago Medicine Northwest Indiana, located at 10855 VIRGINIA ST, CROWN POINT, IN 46307-0210, phone (999) 999-9999 in Crown Point, Indiana. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 and Recurrent Endometrial Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
28 clinical trials at UChicago Medicine Northwest Indiana
·Clear filters·Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Common conditions studied in Crown Point
- Acute Myeloid Leukemia (4 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Recurrent Endometrial Carcinoma (3 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
- Stage IV Lung Cancer AJCC v8 (3 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
Leading research sponsors in Crown Point
- National Cancer Institute (NCI)
- NRG Oncology
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Crown Point?
There are approximately 50 recruiting clinical trials in Crown Point, Indiana listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Crown Point pay participants?
Most recruiting trials in Crown Point compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Crown Point?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Crown Point?
The most common conditions under active study in Crown Point include Acute Myeloid Leukemia (4), Anatomic Stage II Breast Cancer AJCC v8 (4), Recurrent Endometrial Carcinoma (3), Stage IIIB Lung Cancer AJCC v8 (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Crown Point?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Crown Point on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Crown Point?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Crown Point?
Recruiting research sites in Crown Point include UChicago Medicine Northwest Indiana, Northwest Cancer Center - Crown Point, Northwest Cancer Center - Main Campus, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Crown Point right now?
The largest active categories in Crown Point are Cancer & tumors (46). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UChicago Medicine Northwest Indiana?
UChicago Medicine Northwest Indiana is located at 10855 VIRGINIA ST, CROWN POINT, IN 46307-0210. Use the Google Maps link in the intro above to get directions.
How do I contact UChicago Medicine Northwest Indiana?
You can reach UChicago Medicine Northwest Indiana by phone at (999) 999-9999. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.